Department of Clinical Medicine, Medical School of Nantong University, Nantong University, Nantong, China.
PeerJ. 2022 Sep 30;10:e14048. doi: 10.7717/peerj.14048. eCollection 2022.
MicroRNA-21 (miR-21) is significantly expressed in a variety of cancers and could be used as a tumor biomarker. However, the results are varied, and no studies on the diagnostic usefulness of miR-21 in Asian esophageal cancer (EC) patients have been published. This meta-analysis was aimed at exploring whether miR-21 can be used as a diagnostic marker and assessing its effectiveness.
The relevant literature was identified in six main databases: Ovid MEDLINE, PsycINFO, PubMed MEDLINE, Embase, Web of Science, and the Cochrane Library. Two researchers independently selected the literature based on the inclusion and exclusion criteria, extracted data, and evaluated the risk of bias. The meta-analysis was carried out using Review Manager 5.4, Meta-Disc 1.4 and STATA 15.1 software. In the end, 987 patients from 12 different studies were included. Quality evaluation of diagnostic accuracy studies 2 (QUADAS-2) was used to examine the risk of bias.
The pooled sensitivity (SEN) was 0.72 (95% CI [0.69-0.75]), the pooled specificity (SPE) was 0.78 (95% CI [0.75-0.81]), the pooled positive likelihood ratio (PLR) was 2.87 (95% CI [2.28-3.59]), the pooled negative likelihood ratio (NLR) was 0.36 (95% CI [0.31-0.43]), the pooled diagnostic odds ratio (DOR) was 10.00 (95% CI [7.73-12.95]), and the area under the curve 0.82 (95% CI [0.79-0.85]). A Deeks' funnel plot shows that there was no publication bias ( = 0.99).
Our findings suggest miR-21 might be the potential biomarker for detecting EC in Asian populations, with a good diagnostic value.
微小 RNA-21（miR-21）在多种癌症中表达显著，可作为肿瘤标志物。然而，结果存在差异，尚无关于 miR-21 在亚洲食管癌（EC）患者中的诊断有用性的研究。本荟萃分析旨在探讨 miR-21 是否可作为诊断标志物，并评估其有效性。
在 Ovid MEDLINE、PsycINFO、PubMed MEDLINE、Embase、Web of Science 和 Cochrane Library 这 6 个主要数据库中确定了相关文献。两位研究人员根据纳入和排除标准独立筛选文献，提取数据，并评估偏倚风险。使用 Review Manager 5.4、Meta-Disc 1.4 和 STATA 15.1 软件进行荟萃分析。最终，纳入了来自 12 项不同研究的 987 名患者。使用诊断准确性研究 2（QUADAS-2）质量评估工具评估偏倚风险。
汇总敏感性（SEN）为 0.72（95%CI [0.69-0.75]），汇总特异性（SPE）为 0.78（95%CI [0.75-0.81]），汇总阳性似然比（PLR）为 2.87（95%CI [2.28-3.59]），汇总阴性似然比（NLR）为 0.36（95%CI [0.31-0.43]），汇总诊断比值比（DOR）为 10.00（95%CI [7.73-12.95]），曲线下面积（AUC）为 0.82（95%CI [0.79-0.85]）。Deeks 漏斗图显示无发表偏倚（ = 0.99）。
我们的研究结果表明，miR-21 可能是亚洲人群检测 EC 的潜在生物标志物，具有良好的诊断价值。
